Russian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
protease/воспаление
Ссылка сохраняется в буфер обмена
Страница 1 от 238 полученные результаты
Pharmaceutical dosage unit for treating inflammation comprising protease nexin-I
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
TECHNICAL FIELD
The invention relates to the field of treatment of conditions characterized by inflammation or inflammatory responses. More specifically, it concerns treatment of inflammation and inflammatory diseases with protease nexin- 1.
BACKGROUND ART
The structure and recombinant production of
Process of treating inflammation with human urinary thiol protease inhibitor
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
BACKGROUND OF THE INVENTION
The present invention relates to an anti-inflammatory agent comprising as an active component a human urinary thiol protease inhibitor and a process for preparation thereof.
Human urinary proteins are composed mainly of albumin [see "Sogo Rinsho", Vol. 27, P. 1223
Substituted isocoumarins as serine protease inhibitors and anti-inflammatory agents
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to a novel class of heterocyclic compounds useful for selectively inhibiting trypsin-like enzymes, selectively inhibiting chymotrypsin-like enzymes, selectively inhibiting elastase or for generally inhibiting serine
Blockade of inflammatory proteases with cyclic peptides
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
FIELD OF THE INVENTION
This invention relates to the use of cyclic peptides for modulating cytokine activity, including signaling and inflammatory pathways, in various diseases. More particularly, cyclic peptides possess hereto unknown biological activities, such as inhibition of sheddases and other
Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to a novel class of heterocyclic compounds useful for selectively inhibiting trypsin-like enzymes, selectively inhibiting chymotrypsin-like enzymes, selectively inhibiting elastase or for generally inhibiting serine
Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to a novel class of heterocyclic compounds useful for selectively inhibiting trypsin-like enzymes, selectively inhibiting chymotrypsin-like enzymes, selectively inhibiting elastase or for generally inhibiting serine
Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
This invention relates to inhibitors of cysteine proteases, in particular to heteroaryl nitrile cathepsin K inhibitors and to their pharmaceutical use for the treatment or prophylaxis of diseases or medical conditions in which cathepsin K is implicated.
Cathepsin K is a member of the family of
2-substituted-4H-3, 1-benzoxazin-4-ones and benzthiazin-4-ones as inhibitors of complement C1r protease for the treatment of inflammatory processes
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
BACKGROUND OF THE INVENTION
Serine proteases are a group of endopeptidase enzymes which have a serine amino acid in their active center. Representative serine proteases include trypsin, thrombin, and plasmin related to blood coagulation and the fibrinolysis system (Chem. Pharm. Bull., 41(1):117
Treatment of inflammation
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
FIELD OF THE INVENTION
The present invention relates to a method and composition for treating mammals afflicted with inflammatory diseases or injuries. More particularly, the present invention relates to the treatment of certain inflammatory conditions in patients, by administering serine protease
Treatment of inflammation-associated disorders using interleukin-1.beta.-converting enzyme (ICE)/CED-3 family inhibitors
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to programmed cell death and specifically to compositions and methods for ameliorating or preventing inflammation and symptoms associated therewith using interleukin-1.beta.-converting enzyme (ICE)/CED-3
Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
DESCRIPTION OF THE FIELD
Tryptase, the predominant protease secreted from human mast cells, is thought to be involved in neuropeptide processing and tissue inflammation. Tryptase concentrations are elevated in the bloodstream for several hours following anaphylaxis (Schwartz et al. (1987) N. Eng. J.
Methods for treatment of and prophylaxis against inflammatory disorders
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
REFERENCE TO SEQUENCE LISTING
The Sequence Listing submitted Oct. 11, 2018 as a text file named "21101_0371U3_Revised_Sequence_Listing.txt," created on Oct. 9, 2018, and having a size of 2,454 bytes is hereby incorporated by reference pursuant to 37 C.F.R. .sctn. 1.52(e)(5).
TECHNICAL FIELD
The
Methods for treatment of and prophylaxis against inflammatory disorders
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
REFERENCE TO SEQUENCE LISTING
The Sequence Listing submitted Jun. 19, 2019 as a text file named "21101_0371U4_Updated_Sequence_Listing.txt," created on Apr. 3, 2019, and having a size of 2,497 bytes is hereby incorporated by reference pursuant to 37 C.F.R. .sctn. 1.52(e)(5).
TECHNICAL FIELD
The
Mast cell protease peptide inhibitors
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
FIELD OF THE INVENTION
This invention relates to compositions containing a mast cell protease inhibitor and methods for use thereof in the prevention and treatment of inflammatory disorders mediated by mast cell tryptases. Methods utilizing the compositions for identifying additional inhibitors of
Tripeptide epoxy ketone protease inhibitors
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
BACKGROUND OF THE INVENTION
1. Field of the Invention
This disclosure relates to tripeptide epoxy ketone protease inhibitors including methods of making and using the same.
2. Description of Related Technology
In eukaryotes, protein degradation is predominately mediated through the ubiquitin pathway
Самая полная база данных о лекарственных травах, подтвержденная наукой
- Работает на 55 языках
- Травяные лекарства, подтвержденные наукой
- Распознавание трав по изображению
- Интерактивная карта GPS - отметьте травы на месте (скоро)
- Прочтите научные публикации, связанные с вашим поиском
- Ищите лекарственные травы по их действию
- Организуйте свои интересы и будьте в курсе новостей исследований, клинических испытаний и патентов
Введите симптом или заболевание и прочтите о травах, которые могут помочь, введите лекарство и узнайте о болезнях и симптомах, против которых оно применяется.
* Вся информация основана на опубликованных научных исследованиях.
